Category Archives: Genetic Medicine

CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Sarepta and Roche have entered into a licensing agreement providing Roche exclusive commercial rights to SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), Sareptas investigational gene therapy for Duchenne muscular dystrophy (DMD), outside the United States. Under the agreement, Sarepta will receive $1.15 billion in an upfront payment and an equity investment; up to $1.7 billion in regulatory and sales milestones; and royalties on net sales, anticipated to be in the mid-teens. In addition, Roche and Sarepta will equally share global development expenses. Sarepta retains all rights to SRP-9001 in the United States.

The collaboration combines Sareptas leading gene therapy candidate for DMD with Roches global reach, commercial presence and regulatory expertise to accelerate access to SRP-9001 for patients outside the United States. DMD is an X-linked rare degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. SRP-9001, currently in clinical development for DMD, is designed to deliver the micro-dystrophin-encoding gene directly to the muscle tissue for the targeted production of the micro-dystrophin protein.

As a mission-driven organization, we are inspired to partner with Roche with the goal of bringing SRP-9001 to patients outside the United States. This collaboration will not only increase the speed with which SRP-9001 could benefit DMD patients outside the United States, but will also greatly expand the scope of territories within which we could potentially launch SRP-9001 and improve and save lives, said Doug Ingram, president and chief executive officer, Sarepta. In addition to the validation that comes from joining forces with Roche, this licensing agreement one of the most significant ex-U.S. licensing transactions in biopharma will provide Sarepta with the resources and focus to accelerate our gene therapy engine and, if successful, bring SRP-9001 to patients as quickly as possible, potentially transforming the lives of countless DMD patients across the globe.

Said James Sabry, Head of Roche Pharma Partnering, We are excited to enter this licensing agreement with Sarepta. By working together to provide SRP-9001 to patients, we hope to fundamentally transform the lives of patients and families living with this devastating disorder for which there are currently only limited treatment options.

As part of the agreement, Sarepta will continue to be responsible for the global development plan and manufacturing build out for SRP-9001. Through its leading hybrid manufacturing platform, Sarepta will remain responsible for manufacturing of clinical and commercial supplies. Sarepta has also granted Roche an option to acquire ex-U.S. rights to certain future DMD-specific programs, in exchange for separate milestone and royalty considerations, and cost sharing.

The closing of the transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. The parties anticipate that the agreement will close in the first quarter of 2020.

Goldman Sachs & Co. LLC is acting as the lead financial advisor to Sarepta. Morgan Stanley & Co. LLC is also serving as a financial advisor and Ropes & Gray LLP is serving as legal advisor to Sarepta.

Conference Call InformationThe conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 2077714. Please specify to the operator that you would like to join the "Sarepta Therapeutics Conference Call." The conference call will be webcast live under the investor relations section of Sarepta's website at http://www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta TherapeuticsSarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases. For more information, please visit http://www.sarepta.com.

Sarepta Forward-Looking StatementThis press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include but are not limited to statements regarding the closing of the transaction; Sareptas right to receive any upfront payment or equity investment from Roche pursuant to the agreement; Sareptas right to receive regulatory and sales milestones, and royalty payments from Roche pursuant to the agreement; Roches obligation to share global development expenses pursuant to the agreement; the continued development and manufacturing of SRP-9001; SRP-9001 expected delivery of micro-dystrophin-encoding gene directly to the muscle tissue and the expected production of the micro-dystrophin protein; the expected increased speed with which SRP-9001 could benefit patients outside the United States and expansion of territories within which Sarepta could launch SRP-9001; the expectation that the licensing agreement will provide Sarepta with the resources and focus to accelerate its gene therapy engine and potentially bringing SRP-9001 to patients as quickly as possible and transforming the lives of countless DMD patients across the globe; potential regulatory approvals of SRP-9001; and the potential launch and commercialization of SRP-9001.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Known risk factors include, among others, market conditions, the expected benefits and opportunities related to the licensing agreement may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in product research and development and manufacturing limitations; success in preclinical testing and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; our data for SRP-9001 may not be sufficient for obtaining regulatory approval; Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing SRP-9001 to market, for various reasons, some of which may be outside of Sareptas control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions; and those risks identified under the heading Risk Factors in Sareptas most recent Annual Report on Form 10-K for the year ended December 31, 2018 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Companys business, results of operations and the trading price of Sareptas common stock. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at http://www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Investors:Ian Estepan, 617-274-4052iestepan@sarepta.com

Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

See more here:
Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy...

Are you one of the 26 million people who have experienced genetic testing by companies such as 23andMe or Ancestry? These companies promise to reveal what your genes say about your health and ancestry. Genes are, indeed, the instruction book containing the code that makes you a unique human being. This specific code which you inherit from your parents is what makes you, you.

The genetic coding system works amazingly well, but like all systems, occasionally things dont go as planned. You may inherit a gene that increases your chance of developing a health condition and sometimes the code develops an error causing you to have a devastating disease.

If genetic testing is so powerful in analysing and understanding your health, why cant you just as easily have this same genetic information inform your care at the doctors office? To answer this question, lets first look at the field of using genetic information to drive your healthcare (often referred to as precision or personalized medicine).

Across the globe, researchers devote enormous amounts of time and effort to understand how human genes impact health and billions of dollars are invested. The knowledge of what impact specific genes have on our health has increased tremendously and continues to do so at an amazing pace. Our increased understanding of genes, and how they affect our health, is driving novel methods to halt diseases and new ways of thinking about how medications can be developed to treat diseases.

Precision medicine is a growth area

With all this money and effort being expended, why isnt the use of your genetic information a standard part of your medical care? As the Kaiser Permanente Fellow to the World Economic Forums Precision Medicine Team, I recently had the opportunity to interview leaders from every aspect of Precision Medicine to understand the barriers preventing genetic testing from becoming a standard part of your healthcare.

Those with whom I spoke included insurance companies who pay for the tests, doctors who use and interpret them, genetic counsellors who help you understand test results, diagnostic companies which develop testing, government healthcare regulators, researchers making astonishing discoveries and healthcare organizations who are determining how best to deploy genetic testing.

These interviews suggest that the science behind genetic testing and the knowledge of how genes impact health is far ahead of our ability to make full use of this information in healthcare. Moving genetic testing into your doctors office requires a complex set of technologies, processes, knowledge and payments. Though many of the barriers inhibiting this movement were unique and complex, there were some consistent and common themes:

1. The limited expertise in genetics within healthcare systems. The need for education of healthcare providers as well as the public was regularly highlighted. The use of genetics in healthcare requires specialized knowledge that is outside the expertise of most doctors. Healthcare providers simply dont have time to study this new and rapidly changing information as their hands are full just keeping up with the latest trends and findings in their specialities. Additionally, education on genetics in healthcare is needed for the public. As one person interviewed said: The public watches CSI and thinks the use of DNA and genetics is black and white; using genetics in healthcare is rarely black and white

2. The lack of sufficient genetic counsellors. Genetic counsellors are often used to engage patients prior to testing and after results have been received, providing them with the detailed and nuanced information required for many of these tests. They also support doctors when they need assistance in making decisions about genetic testing and understanding the test results.

3. To successfully embed genetics into your care, doctors need the workflows for genetic testing (receiving results and understanding the impact on their care plans) to become a seamless part of their work. Clinical decision support software for genetics should alert the healthcare provider when genetic testing is merited with a patient, based on information the provider has entered during their examination. The software should then provide a list of appropriate tests and an explanation of why one might be used over another. After doctors order the test, they believe is most appropriate, the system should inform them of the results in clear, easily understandable language. The results should inform the doctor if the care plan for this patient should be modified (with suggestions for how the care should change).

4. Coverage of payments for genetic testing. If such tests are not paid for by insurers or government healthcare agencies (the payers), doctors simply wont order them. In the US and many other countries, there is patchwork coverage for genetic testing. Some tests are covered under specific circumstances, but many are not covered at all. The major reason cited by the payers for not covering genetic testing is a lack of evidence of clinical efficacy. In other words, do these tests provide actionable information, that your doctor can use to ensure better health outcomes? Until the payers see sufficient evidence of clinical efficacy, they will be hesitant to pay for many types of genetic testing. Doctors are concerned about the same thing, according to my research. They want to see the use of these tests in large populations, so they can determine that there is a benefit to using them.

Using your genetic information in healthcare is much more complex than taking a direct-to-consumer genetic test such as those offered by 23andMe. Healthcare is a multifaceted system and doctors already have too much on their plate. As such, there must be sufficient proof that the use of genetic testing will result in better health outcomes for the populations these clinicians serve before it's introduced into this setting.

We cannot hesitate in the face of the above complexities. As I completed the interviews which revealed these barriers, I stumbled across a journal article on this very subject. Written by a prominent group of doctors and researchers from government and leading universities in 2013, it highlights these same barriers and that virtually no progress has been made in the ensuing seven years. This is why I am focusing my fellowship at the World Economic Forum on a new project called Moving Genomics to the Clinic. Taking advantage of the multistakeholder platform of the Forum, the project will quicken the pace of tackling these barriers so that the use of genetic information can become a standard part of your healthcare experience.

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.

Written by

Arthur Hermann, Fellow, Precision Medicine, World Economic Forum

The views expressed in this article are those of the author alone and not the World Economic Forum.

See more here:
How to bring precision medicine into the doctor's office - World Economic Forum

A group led by researchers at Baylor College of Medicine has identified significant differences at the epigenetic level the chemical tags in DNA that help regulate gene expression between two clinically distinct forms of acute childhood malnutrition known as edematous severe acute malnutrition (ESAM) and non-edematous SAM (NESAM).

The researchers report in the journal Nature Communications that ESAM, but not NESAM, is characterized by a reduction in methyl chemical tags in DNA and complex changes in gene activity, including both enhanced and reduced gene expression. Some of the genes that lost their methyl tags have been linked to other disorders of nutrition and metabolism, such as abnormal blood sugar and fatty liver disease, conditions that also have been observed in ESAM. The findings support consideration of methyl-group supplementation in ESAM.

Severe acute childhood malnutrition presents in two clinically distinct forms: ESAM and NESAM, said corresponding author Dr. Neil Hanchard, assistant professor of molecular and human genetics and the USDA/ARS Children's Nutrition Research Center at Baylor. ESAM is characterized by body swelling and extensive dysfunction of multiple organs, including liver, blood cells and the gut, as well as skin and hair abnormalities. NESAM, on the other hand, typically presents with weight loss and wasting.

The differences between ESAM and NESAM are still not fully explained despite decades of studies addressing this question. In the current study, Hanchard and his colleagues looked to better understand the conditions by investigating whether there were differences at the molecular level, specifically on DNA methylation.

The decision to look at DNA methylation was partly driven by previous studies looking at biochemical markers in these individuals. In particular, the turnover of a particular amino acid called methionine, said Hanchard.

Previous work has shown that methionine turnover is slower in ESAM than in NESAM. Methionine is a central ingredient of 1-carbon metabolism, a metabolic pathway that is key to DNA methylation. Lower methionine turnover suggested the possibility of alterations in DNA methylation.

First, we conducted a genome-wide analysis of DNA methylation. When we found in children acutely ill with ESAM genes with levels of DNA methylation that were significantly different from those in NESAM patients, the levels were always lower. Of the genes analyzed, 161 showed a highly significant reduced level of methylation in ESAM, when compared to the same genes in NESAM, Hanchard said.

Interestingly, a group of adults who had recovered from having ESAM malnutrition in their childhood did not show the same reduction in DNA methylation the researchers observed in childhood acute cases. This suggested that lower DNA methylation was probably related to acute ESAM.

Knowing that DNA methylation helps regulate gene expression, Hanchard and his colleagues next investigated whether there were differences in gene expression between ESAM and NESAM. They found that reduced overall methylation in ESAM resulted in a complex pattern of gene expression changes. For some genes, having reduced methylation enhanced their expression, while for others it reduced it.

Among the genes that were highly affected by reduced methylation were some of those related to conditions such as blood sugar regulation, fatty liver disease and other metabolic problems, which are also commonly seen more often in ESAM than NESAM.

Our findings contribute to a better understanding of the molecular events that likely result in the differences between ESAM and NESAM, Hanchard said. Although we still dont know why malnutrition leads to ESAM in some children, while it results in NESAM in others, our findings suggest that, once ESAM gets on its way, methylation changes are likely involved in the clinical signs and symptoms of the condition. There is also evidence that individual genetic variation also influences the level of DNA methylation. Furthermore, I am excited about the possibility that altering the molecular outcome of malnutrition with specific interventions could one day help alter the clinical outcome.

Other contributors to this work include first author Katharina V. Schulze, Shanker Swaminathan, Sharon Howell, Aarti Jajoo, Natasha C. Lie, Orgen Brown, Roa Sadat, Nancy Hall, Liang Zhao, Kwesi Marshall, Thaddaeus May, Marvin E. Reid, Carolyn Taylor-Bryan, Xueqing Wang, John W. Belmont, Yongtao Guan, Mark J. Manary, Indi Trehan and Colin A. McKenzie.

See a complete list of author affiliations and financial support for this study.

See the article here:
Form of severe malnutrition linked to DNA modification - Baylor College of Medicine News

The holidays are supposed to be a time of joy and celebration, but for some, money worries coupled with family stress can trigger depression.

Studies have shown as many as 30% to 60% of people who take antidepressants do not get adequate relief from depression.

Now, a team of Philadelphia researchers is looking beyond the head to the gut for answers.

Researchers at the University of Pennsylvania and Children's Hospital of Philadelphia conducted a study that demonstrates the biological interaction between brain and gut, starting in animals.

"We were able to show that gut bacteria from stress-vulnerable rats, if you introduce that into a rat that had never been exposed to stress, that rat would now have some of the depressive characteristics of the rat that was stress-vulnerable," research associate Jiah Pearson-Leary said.

Turns out, becoming more vulnerable from this gut bacteria that caused the stress created another problem in the animals: how they coped with stress.

"Animals that are more passive in coping with stress show more vulnerability because they exhibit behaviors that are more hopeless, depressive-type state," said Dr. Seema Bhatnagar, a professor of anesthesiology.

Scientists say stress changes the gut microbiome and increases inflammation in the brain. There's a growing body of evidence that brain inflammation is associated with depression.

So, what do the findings mean for humans? Researchers believe future studies will show that altering gut bacteria, possibly with probiotics, might pave the way for treating psychiatric disorders, including depression.

It is research, from bench to bedside, that could someday make a big difference in mental health.

Probiotics are live bacteria that help restore the balance of microbes in the gut and can be taken in a supplement form.

Scientists nationwide have widely studied the impact of probiotics on digestive diseases like Crohn's, but the Philadelphia team is among a few in the country considering the potential impact of probiotics and mental health.

MEDICAL BREAKTHROUGHSRESEARCH SUMMARYTOPIC: TREAT THE GUT, TREAT DEPRESSION: MEDICINE'S NEXT BIG THING?REPORT: MB #4673

BACKGROUND: Depression is one of the most common mental disorders in the U.S. Current research suggests that depression is caused by a combination of genetic, biological, environmental, and psychological factors. Depression can happen at any age, but often begins in adulthood. Depression is now recognized as occurring in children and adolescents, although it sometimes presents with more prominent irritability than low mood. Many chronic mood and anxiety disorders in adults begin as high levels of anxiety in children. Depression, especially in midlife or older adults, can co-occur with other serious medical illnesses, such as diabetes, cancer, heart disease, and Parkinson's disease. These conditions are often worse when depression is present. (Source: https://www.nimh.nih.gov/health/topics/depression/index.shtml)

TREATMENT: Lifestyle changes to help with depression include exercise, nutrition, social support, sleep, and stress reduction. There are also many types of therapy available. Three of the more common methods used in depression treatment include cognitive behavioral therapy, interpersonal therapy, and psychodynamic therapy. Often, a blended approach is used. Depression medication may be the most advertised treatment for depression, but that doesn't mean it is the most effective. Depression is not just about a chemical imbalance in the brain. Medication may help relieve some of the symptoms of moderate and severe depression, but it doesn't cure the underlying problem, and it's usually not a long-term solution. Antidepressant medications also come with side effects and safety concerns, and withdrawal can be very difficult. (Source: https://www.helpguide.org/articles/depression/depression-treatment.htm)

NEW RESEARCH: Seema Bhatnagar, PhD, Associate Professor of Anesthesiology at the University of Pennsylvania said, "In a context where there are stressful life events and we believe these inflammatory processes are important both in the gut and the brain, you want to reduce inflammatory processes. I think the best advice anyone could give is to maintain a healthy body - sleep, exercise, stress reduction techniques. There are a number of probiotics people like to take, and there's anecdotal evidence that it works for some people, but there's not a lot of experimental evidence. There is accumulating evidence that prebiotic substances that actually promote the growth of certain types of bacteria - those might be a better way to promote a healthy gut." (Source: Seema Bhatnagar, PhD)

More here:
Treat the gut, treat depression: Medicine's next big thing? - WNDU-TV

NEW YORK, Dec. 19, 2019 /PRNewswire/ --The New York Genome Center (NYGC) announced today that Hackensack Meridian Health and the Georgetown Lombardi Comprehensive Cancer Center have become the two newest institutional associate members of the NYGC.

Hackensack Meridian Health is New Jersey's largest health care network. Its Center for Discovery and Innovation (CDI) and John Theurer Cancer Center at Hackensack University Medical Center, a member of the Georgetown Lombardi consortium, are key components of the network's strategy to develop and employ the latest genomic medicine for patients. Georgetown Lombardi Comprehensive Cancer Center is Washington, D.C.'s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and NCI-approved consortium.

"We are excited to have these leading institutions with distinguished physician-scientists and researchers join the New York Genome Center community," said Tom Maniatis, PhD, Evnin Family Scientific Director and Chief Executive Officer, NYGC. "We look forward to working with their teams to further our collaborative efforts to accelerate genomics research."

"The Center for Discovery and Innovation is a key element of our mission to transform health care and lead toward the future," said Robert C. Garrett, FACHE, Chief Executive Officer, Hackensack Meridian Health. "The John Theurer Cancer Center continues to provide the most advanced care currently available. Through our new partnerships at the New York Genome Center, patients in New Jersey and beyond will benefit from the latest technologies for personalized medicine."

"The New York Genome Center is a unique and critical nexus for research collaboration in the genomics community, and the Georgetown Lombardi Comprehensive Cancer Center consortium is pleased to join NYGC's member institutions to partner in cancer genomics research," said Louis M. Weiner, MD, Director, Georgetown Lombardi Comprehensive Cancer Center and the MedStar Georgetown Cancer Institute.

The new members are joining the NYGC through two separate partnerships with distinct collaborative research objectives. The first partnership, to be led by Hackensack Meridian Health's CDI, is focused on exploring the genetics underlying the risk factors for behavioral disorders and identifying genetic markers that help physicians predict and manage these disorders more effectively. The second partnership is focused on cancer genomics and led by Georgetown Lombardi Comprehensive Cancer Center, which includes investigators from Georgetown University Medical Center, along with the Hackensack Meridian Health's John Theurer Cancer Center and CDI. This partnership will seek to use advanced genetic analyses to better understand risk factors for emergence of certain aggressive cancers, such as pediatric brain tumors; why certain cancers fail to respond to immunotherapy; and identify genetic markers or cellular factors that can improve patient outcomes.

"This is a leap forward for the CDI and its mission to translate scientific innovation from the laboratory to treatments for patients," said David S. Perlin, PhD, Chief Scientific Officer and Senior Vice President of the CDI. "Our world-class scientists will benefit from connecting and collaborating with colleagues at leading New York-region institutions."

Given their areas of research focus, Hackensack Meridian Healthand Georgetown Lombardi Comprehensive Cancer Center will be participants in the Genome Center Cancer Group (GCCG), NYGC's founding scientific working group, which is composed of clinicians and cancer researchers from NYGC's member institutions. With the addition of these new members, the GCCG now includes seven NCI-designated Comprehensive Cancer Centers. The GCCG is led by Nobel Laureate Harold Varmus, MD, Senior Associate Core Member, NYGC, and Lewis Thomas University Professor of Medicine, Weill Cornell Medicine, and Charles Sawyers, MD, Chair, Human Oncology and Pathogenesis Program, Marie-Jose and Henry R. Kravis Chair, Memorial Sloan Kettering Cancer Center, and Affiliate Member, NYGC. The GCCG recently launched Polyethnic-1000, a project to study cancer in ethnically diverse, underserved patient populations, and is also spearheading the multi-institutional Very Rare Cancer Consortium, a research cohort focused on understanding the genetic causes for rare, understudied cancers. In addition, the NYGC is utilizing the application of novel statistical approaches and population-level analyses to major cohorts in cancer genomics.

Researchers from Hackensack Meridian Health's CDI also are expected to engage in NYGC's Neuropsychiatric Disease Scientific Working Group. It is led by Dr. Maniatis; Michael Zody, PhD, Scientific Director, Computational Biology; and Thomas Lehner, PhD, MPH, formerly of the National Institute of Mental Health of the National Institutes of Health, who arrives to the NYGC in January in the new position of Scientific Director of Neuropsychiatric Disease Genomics. Reporting to Dr. Maniatis, Dr. Lehner will lead the expansion of the NYGC's innovative, large-scale whole genome autism research into other neuropsychiatric disease areas, including schizophrenia and bipolar disorder.

Georgetown Lombardi Comprehensive Cancer Center and Hackensack Meridian Health join NYGC's institutional associate members, which include American Museum of Natural History, Hospital for Special Surgery, The New York Stem Cell Foundation, Princeton University, and Roswell Park Cancer Institute, and its 12 institutional founding members: Cold Spring Harbor Laboratory, Columbia University, Albert Einstein College of Medicine, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, New York University, Northwell Health, The Rockefeller University, Stony Brook University, and Weill Cornell Medicine.

About the New York Genome Center The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer. Leveraging our strengths in whole genome sequencing, genomic analysis, and development of new genomic tools, the NYGC serves as a nexus for collaboration in disease-focused genomic research for the New York medical and academic communities and beyond.

NYGC harnesses the expertise and builds on the combined strengths of our faculty, staff scientists, member institutions, scientific working groups, affiliate members, and industry partners to advance genomic discovery. Central to our scientific mission is an outstanding faculty who lead independent research labs based at the NYGC, and hold joint tenure-track appointments with one of our member institutions.

Institutional founding members of the NYGC are: Cold Spring Harbor Laboratory, Columbia University, Albert Einstein College of Medicine, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, New York-Presbyterian Hospital, New York University, Northwell Health, The Rockefeller University, Stony Brook University, and Weill Cornell Medicine. Institutional associate members are: American Museum of Natural History, Georgetown Lombardi Comprehensive Cancer Center, Hackensack Meridian Health, Hospital for Special Surgery, The New York Stem Cell Foundation, Princeton University, and Roswell Park Cancer Institute.

For more information on the NYGC, please visit:http://www.nygenome.org.

Media Contact:Karen Zipern, Director, Communications, NYGCkzipern@nygenome.org o: 646-977-7065c: 917-415-8134

View original content:http://www.prnewswire.com/news-releases/hackensack-meridian-health-and-georgetown-lombardi-comprehensive-cancer-center-become-associate-members-of-the-new-york-genome-center-300977742.html

SOURCE New York Genome Center

Read more:
Hackensack Meridian Health and Georgetown Lombardi Comprehensive Cancer Center Become Associate Members of the New York Genome Center - P&T Community

UNC Police is asking the public for help in their investigation of a series of credit card thefts fromdifferent medical research buildings on south campus earlier this month.

The department tweeted out photos on Tuesday morning, asking for helping identifying two people of interest in relation to the investigation.

According to an Alert Carolina post made on December 5, the thefts occurred during business hours on Wednesday December 4 inMacNider Hall, Beard Hall, the Bioinformatics Building and the Genetic Medicine Research Building among others. The post says credit cards were taken from unsecured offices and cubicles throughout the buildings.

Anyone seeing any suspicious activity anywhere on campus is reminded to call 911 immediately. UNC Police also encourage people to use smart security practices while in a work environment, like putting away visible valuables, keeping a record of all keys that have been issued and no admitting strangers into places of work.

If you have any information about the individuals, call the UNC Police Department at (919) 962-8100.

Related

See the original post:
UNC Police Investigating Series of Credit Card Thefts on South Campus - Chapelboro.com